Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters

Osteoporosis is a complication of type 2 diabetes mellitus (T2DM). Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance. However, the effect of denosumab (a human monocl...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2019-11, Vol.98 (47), p.e18067-e18067
Main Authors: Abe, Ichiro, Ochi, Kentaro, Takashi, Yuichi, Yamao, Yuka, Ohishi, Hanako, Fujii, Hideyuki, Minezaki, Midori, Sugimoto, Kaoru, Kudo, Tadachika, Abe, Makiko, Ohnishi, Yasushi, Mukoubara, Shigeaki, Kobayashi, Kunihisa
Format: Article
Language:English
Subjects:
Aged
Blood Glucose - drug effects
Bone Density Conservation Agents - pharmacology
Bone Density Conservation Agents - therapeutic use
Denosumab - pharmacology
Denosumab - therapeutic use
Diabetes Complications - drug therapy
Diabetes Complications - metabolism
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Female
Humans
Male
Observational Study
Osteoporosis - etiology
Osteoporosis - metabolism
RANK Ligand - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoporosis is a complication of type 2 diabetes mellitus (T2DM). Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance. However, the effect of denosumab (a human monoclonal antibody of RANKL) upon glycemic and metabolic parameters is controversial. We revealed the effect of denosumab upon glycemic and metabolic parameters for 52 weeks. We evaluated 20 individuals diagnosed with both osteoporosis (male and female: postmenopausal) and T2DM. We measured glycemic and metabolic parameters before and 26/52 weeks after administration of denosumab (60 mg per 26 weeks) without changing any other medication each patient was taking. All patients completed the study without complications and the T-score (lumbar spine and femoral neck) improved significantly from baseline to 52 weeks after denosumab administration (P 
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000018067